Introduction
Pre-eclampsia remains a major cause of maternal and perinatal mortality and morbidity in the United Kingdom. The commonest mode of maternal death is cerebrovascular haemorrhage, although hepatic and renal failure and disseminated intravascular coagulation also contribute. The fetus is compromised by uteroplacental vascular damage and ischaemia which can result in intra-uterine growth retardation, iatrogenic prematurity and perinatal death. This widespread pathology illustrates the multisystem nature of the disease process which can affect virtually every organ and system in the body with hypertension representing only one facet of an extensive and poorly understood disease process. The common feature of all the pathological manifestations of the disease is vascular damage and dysfunction.
Pathology of the placental bed
In normal pregnancy, a series of physiological changes occur in two stages as the spiral arteries of the placental bed are invaded by the cytotrophoblast. 1 ,2 In the first trimester the cytotrophoblast penetrates the decidual spiral arteries and migrates down these vessels. This endovascular trophoblast then invades the vessel wall removing the endothelium, internal elastic lamina and muscular coat of the vessel which are replaced by fibrinoid material. By the end of the first trimester virtually every spiral artery in the decidua basalis will have undergone these changes." A second wave of cytotrophoblast invasion occurs in the early part of the second trimester and the endovascular trophoblast similarly transforms the myometrial segments of the spiral arteries and sometimes even the distal segments of the radial arteries.s-« These physiological changes convert the vessels from muscular end arteries to wide-mouthed sinusoids, so transforming the vascular supply from a high pressure-low flow system to a low pressure-high flow system? to meet the needs of the fetus and placenta. Furthermore, loss of the endothelium and muscular layers render the vessels unable to respond to vasomotor stimuli.
In pre-eclampsia trophoblast invasion is somehow impaired and only about half to two-thirds of the decidual spiral arteries undergo these physiological changes.s Furthermore, the conversion of myometrial components of the spiral arteries fails to occur even in vessels where the decidual segments have undergone physiological change. [9] [10] [11] This suggests that the primary invasion of trophoblast is partially impaired, and the second wave fails to occur or is inhibited. Thus, a qualitative and quantitative restriction in the physiological process of trophoblast invasion results in reduced placental blood flow.? This will become more threatening as the pregnancy advances and the demands of the conceptus increases. Additionally, as the vessels maintain their muscular coats, they remain sensitive to vasomotor stimuli.
Pre-eclampsia is also associated with a typical though nonspecific muscular lesion termed 'acute atherosis'12-14 which can be seen in the intramyometrial segments of the spiral arteries in the placental bed, the basal arteries and the decidual parietalis but not in the intradecidual vessels of the placental bed which have undergone physiological change. This was first noted by Hertig in 1945 15 and was subsequently termed acute atherosis because of the presence of foam cells in the damaged vessel wall. Acute atherosis is a necrotizing arteriopathy characterized by fibrinoid necrosis, accumulation of lipid laden macrophages and damaged cells, fibroblast proliferation and a mononuclear cell perivascular infiltrate.t-In the early stages, this lesion is characterized by endothelial damage, insudation of the plasma constituents into the vessel wall, cell proliferation and medial necrosis of the lipid containing muscle cells. 16 The lipid released is subsequently taken up by macrophages which accumulate in the vessel wall. More recently Shanklin and Sibai!? have shown that endothelial damage can be seen ultrastructurally in the decidua at sites outwith the placental bed throughout the maternal-fetal boundary. In addition, they showed more direct correlation to the degree of maternal hypertension, although other workers have shown a correlation with plasma uratelf highlighting the value of urate in predicting severity in pregnancy-induced hypertension (PIH). It has been suggested that in view of some evidence of IgM and complement deposition in these lesions and the perivascular mononuclear infiltrate, that this lesion may be triggered by a maternal immune reaction against the trophoblast. 14 Failure of trophoblast invasion and acute atherosis are not specific to pre-eclampsia as these lesions can be seen in normotensive intrauterine growth retardation,1O.19.20 chronic and nonproteinuric gestational hypertension.s! Furthermore, this is not an all or none phenomenon as there is a great deal of variation in the extent of these pathological findings in the hypertensive disorders of pregnancy.s! These abnormalities in the maternal placenta may produce ischaemia of the fetal placenta. Pathological examination of the fetal placenta in pre-eclampsia reveals infarcts, patchy necrosis and intracellular damage of the syncytiotrophoblast, and an increase in villous cytotrophoblastic cells. 22
The kidney
A number of pathological renal changes occur in pre-eclampsia and these tend to parallel the clinical situation in terms of severity.23-26 The glomeruli enlarge and sometimes bulge and protrude into the proximal tubule due to swelling and vacuolation of the cytoplasm of the glomerular endothelial cells in the capillary loops, thus narrowing the lumen. These glomerular changes were termed 'glomerular endotheliosis' by Spargo et al. 26 The primary change occurs in the endothelial cells although the underlying pathological process is not clear. The epithelium of the glomerulus and its foot processes are essentially normal except for a few intracytoplasmic hyaline droplets. The mesangium however widens with an increase in mesangial matrix and expansion of the mesangial cell cytoplasmic foot processes. These processes can grow round the capillary between the endothelium and the basement membrane.27 Deposits of IgM and fibrin may also be found, but there is no evidence of any other immunoglobulin or complement deposition.P? Just as in the placental bed these changes, although characteristic of preeclampsia, are not specific to it, as similar changes can be seen in abruption.s" They may be related to low grade disseminated intravascular coagulation (DIC) and fibrin deposition which can occur in both conditions. There is no major tubular damage in pre-eclampsia although dilatation and epithelial thinning of the proximal tubules and hyaline deposition, related to protein reabsorption, have been noted,25 as has tubular necrosis. 23 The renal damage of pre-eclampsia can be severe enough to produce acute renal failure either by tubular or cortical necrosis.w Functionally, the glomerular damage is manifest by reduced glomerular filtration rate and renal plasma flow, which are significantly lower than values found in normal pregnancy. 30 However, the most obvious clinical sign of glomerular dysfunction is proteinuria which is a measure of disease severity being associated with poor maternal outcomes. 31. 32 The proteinuria is moderately nonselective in terms of molecular size. 28 . 3 J- 35 While glomerular dysfunction is the underlying cause of proteinuria, the precise mechanism is unclear and could be related to microvascular damage and dysfunction perhaps with loss of the strong negative charges which normally repel proteins from the glomerular endothelial basement membrane.
The liver
Hepatic lesions seen in pre-eclampsia include lake haemorrhage, periportal fibrin deposition within the lake haemorrhages, and areas of infarction and necrosis.s> Thrombosis of the capillaries of the portal tract and small branches of the hepatic arteries is also seen. These haemorrhages probably arise in the arteries of the portal tract which show evidence of vascular damage similar to that seen in other sites in the disease. These changes can be seen in 60% of women dying of pre-eclampsia. These hepatic lesions may be related to activation of the coagulation system, endothelial damage and vasoconstriction. The lesions are not specific to pre-eclampsia as similar changes can be seen in major obstetric haemorrhage.x
The pathological changes in the liver are associated with biochemical evidence of dysfunction and damage which is manifest as elevated liver enzymes including SGOT/SGPTJ7,38 and 'Y glutamyl transferase, elevated bilirubin levels and subsequently clinical jaundice. This may progress to hepatic failure or even subcapsular haematoma or hepatic rupture which are associated with maternal death in pre-eclampsia. Clinically, these changes may produce vomiting and epigastric pain and tenderness. While such symptoms are usually indicative of a fulminating disease process, they may be absent and screening for hepatic dysfunction should be performed in women with the disorder. Deranged liver function tests are not uncommon, with 21% of 355 patients studied by Romero et al 39 having elevated levels of SGOT.
This frequency is similar to that seen in other studies. 37 ,38 Elevated SGOT is associated with severe disease and an increased risk of premature delivery and intrauterine growth retardation.s? As the neonatal complications are independent of the severity of hypertension and the presence of proteinuria, hepatic dysfunction is likely to
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The brain
Eclampsia is one of the most extreme clinical manifestations of cerebral involvement in pre-eclampsia. The pathological features include cerebral oedema, cerebral haemorrhage, petechial haemorrhages, thrombotic lesions and fibrinoid necrosis. 25 ,40 ,4 1 and are again a reflection of vascular damage. Cerebral oedema is not a constant feature but may be seen on computerized tomography (CT) scanning of the brain in eclamptic patients. 42 ,43 The latter study by Richards et al. showed cerebral oedema to be present on CT scanning in 27 or 43 women with neurological complications secondary to preeclampsia, and this correlated with the duration of intermittant seizures suggesting that oedema is not the primary cause of the symptoms and signs of eclampsia or the cause of the seizures, but a secondary feature occurring after seizures.
Cardiovascular and renin-angiotensin system
In contrast to the normal pregnant situation, a contracted plasma volume occurs in pre-eclampsia.vt This is associated with an increase in systemic vascular resistance, a reduction in cardiac output and reduced cardiac preload.s> The key component of this process is likely to be vasoconstriction, possibly mediated by humoral factors or increased vascular sensitivity as there is no increase in autonomic activity.
In normal pregnancy there are substantial changes in the renin-angiotensin system. Plasma renin concentration (PRC), renin substrate and angiotensin II (All) all increase throughout gestation reaching a peak around term. [46] [47] [48] Following delivery, active renin and All falls within two hours of delivery which is in keeping with the half-life of renin in the circulation. Subsequently, there is a rebound to levels greater than those in the nonpregnant situations? which is compatible with the loss of an inhibitory factor on renal renin production. The increase in plasma renin concentration in pregnancy appears therefore to have an extra-renal source. Renin can be produced from the myometrium, decidua, placenta and fetal membranes 5 0-53 and is indistinguisable, immunologically and enzymatically, from renin of renal origin.v' Renin substrate can also be produced from intrauterine tissues. Immunohistochemical staining for renin shows renin containing granules in clusters of cells round the spiral arteries in the myometrium close to the endometrium. 53 These may function in a similar manner to the juxtaglomerular apparatus in the kidney. Thus it appears that a complete reninangiotensin system is present in the intrauterine tissues. This intrauterine system may, just as in the kidney, playa role in the regulation and control of local blood flow.
Despite the increased levels of All in pregnancy blood pressure falls. This reflects the well documented vascular insensitivity to All seen in normal pregnancy which peaks in the second trimester then slowly returns towards the normal nonpregnant situation.55-57 This insensitivity may be partly related to high progesterone concentration, which can blunt the renal effects of All in the nonpregnant and the pressor effects in late pregnancy58.59 possibly by suppressing All receptors; however, it is most likely related to production of vasodilator prostaglandins. Angiotensin II stimulates the production of vasodilator prostaglandins from the vessel wall 60 and inhibitors of prostaglandin synthesis potentiate the vasoconstrictor effects of All in umbilical artery in vitro while PGE z will attenuate it. 61 This effect can also be seen in vivo in the human with indomethacin enhancing pressor effects 6Z and PGE z and PGI z infusions blunting the pressor response further in human pregnancy.63.64 These data suggest that the attenuation of the pressor effects of All in normal pregnancies is due to the stimulation of vasodilator prostaglandins by All to maintain local blood flow just as in the renal circulation. This system may also playa role in the local control of uteroplacental flow. Activation of the intra-uterine renin-angiotensin system and subsequent prostaglandin production will result in local vasodilation despite the increase in pressor agents. This is supported by studies showing that All infusions into the uterus in monkeys will increase both prostaglandin production and blood flow, an effect which can be abolished with inhibitors of prostaglandin synthesis such as indomethacin. 65.66 Conversely, angiotensin converting enzyme inhibitors will reduce both uterine prostaglandin production and blood flow 67 and these substances are therefore contra-indicated for the treatment of pre-eclampsia. Thus, the renin-angiotensin system may have an important physiological role in maintaining and controlling uteroplacental blood flow in normal pregnancy.
Methodological problems and the study of groups varying in disease severity, have made it difficult to determine precisely what changes occur in the renin-angiotensin system in preeclampsia. However, there appears to be two patterns depending on the disease severity. In late onset nonproteinuric pre-eclampsia plasma renin activity increases 68,69 while All may be unchanged or increased.w-"! Early onset proteinuric pre-eclampsia is associated with reduced plasma renin activity, All and aldosterone concentrations. 46, 69, 72 The pressor response to All returns to nonpregnant levels in pre-eclampsia antedating the development of clinically evident disease.s? This increase in the All pressor response is the basis of the angiotensin sensitivity test which has been employed successfully in the late second trimester to identify women with a high risk of subsequently developing pre-eclampsia. It may be due to increased All receptors'P and can be seen in isolated resistance vessels of women with the disease.Z-Reduced production of vasodilator prostaglandins from umbilical arteries in preeclampsia in response to All also occurs,75 and deficient PGI z production is a feature of pre-eclampsia, as discussed below. An increase in All binding sites in platelets in women with pre-eclampsia compared to normal pregnancy has been reported.P Should this antedate the development of the disease it might facilitate identification of women destined to develop the disease.
Pathophysiologically, the changes which occur in the renin-angiotensin system with regard to renal perfusion may be similar to those which occur in pre-eclampsia in the uteroplacental bed with its intrinsic renin-angiotensin system. In the kidney when perfusion is impaired the juxtaglomular apparatus releases renin which in turn stimulates All production and subsequent peripheral vasoconstriction and increased arterial pressure to improve renal perfusion.?o The increased All in the renal vascular bed stimulates the release of vasodilatory prostaglandins. Thus, increased perfusion pressure and systemic vasoconstriction occur simultaneously with intrarenal vasodilation therefore protecting the renal vasculature from the vasoconstrictor effects of AII,77 In pre-eclampsia the critical lesion is failure of trophoblast invasion into the maternal vasculature which will reduce flow and lead to tissue ischaemia. In experimental animals reduction of flow is associated with stimulation of the renin-angiotensin system, hypertension and proteinuria.I" while All and angiotensin converting enzyme inhibitors will respectively enhance and reduce prostaglandin production and blood f1ow. 67,79 Broughton Pipkin and Symonds?» therefore suggest that in late onset nonprotein uric pre-eclampsia, significant ischaemia due to failure of trophoblast invasion occurs late in pregnancy. The impaired perfusion is sensed by the renin-secreting cells round the spiral arteries (the uterine equivalent of the juxtaglomerular apparatus), renin is released and AI and All production occurs. This results in an increase in blood pressure to enhance uteroplacental perfusion pressure. In the uteroplacental bed All stimulates the release of vasodilator prostaglandins from the endothelium, therefore protecting the local circulation and maintaining flow. Thus, activation of the reninangiotensin system may be an attempt to compensate for impaired uteroplacental perfusion. This is in keeping with the established relatively good prognosis for such patients. In contrast, in early onset proteinuric pre-eclampsia there is reduced perfusion of the uteroplacental bed which stimulates the renin-angiotensin system to increase blood pressure in an attempt to improve perfusion. As these patients are deficient in production of vasodilator prostaglandins the compensatory vasodilation in the uteroplacental or renal vascular bed fails resulting in further damage and subsequent placental insufficiency and proteinuria. This has a poorer prognosis than late onset nonproteinuric disease. As the compensatory mechanism of prostaglandin production is impaired less All is required to provoke a vasoconstrictor effect. If there is a negative feedback on the renin-angiotensin system by increased blood pressure per se and by increased atrial natriuretic peptide, then renin and
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All may be reduced in keeping with the findings in pre-eclampsia. Despite this reduction, the lack of prostaglandin production means that lower All concentration could still exert considerable pressor effect.
Platelets and the coagulation system in pre-eclampsia
Widespread deposition of fibrin associated with vascular damage in the placental bed or glomerulus suggests that the coagulation system is activated.w-" This probably represents a secondary phenomenon consequent upon vascular damage. Nonetheless it will still contribute to this damage, promoting a positive feedback loop. Routine coagulation tests are essentially normal, unless pre-eclampsia is complicated by fullblown disseminated intravascular coagulation. BO The normal prothrombin and activated partial thromboplastin times and slightly prolonged thrombin time do not imply that significant coagulation activation is not occurring, as these tests are relatively insensitive. Elevated levels of fibrinopeptide AB2 (a sensitive indicator of coagulation activation which is cleaved from fibrinogen by the action of thrombin) suggests that fibrinogen breakdown occurs in severe disease. Fibrinogen increases in hypertensive compared to normal pregnancy.P although this may simply be an acute phase reactant increasing in response to the disease in general. There is an increase in Factor VIlle activity83,84 but the increase in von Willebrand's factor antigen is greater.e> This increased ratio of von Villebrand's factor antigen to Factor VIllc was initially thought to reflect consumption of Factor VIlle after activation; however, we now know that these two substances are distinct entities which join together in the circulation to form a macro-molecular complex. Factor VIlle is produced by the liver while von Willebrand's factor is synthesized by the vascular endothelium in response to damage. This increase in von Willebrand's factor is likely to reflect endothelial damage. Most of the individual coagulation factors are unchanged. A prospective study found a slight increase in Factor XII and a slight reduction in Factors X and XI in women who went on to develop pre-eclampsia.s« Antithrombin III is reduced, in keeping with the low grade disseminated intravascular coagulation which occurs,83.87 and disseminated intravascular coagulation which occurs,83.87and correlates with disease severity.sf Protein C is reduced in severe disease.s? In general, only minimal coagulation activation occurs, although this may progress to complete disseminated intravascular coagulation in some severe cases.
Activation of the coagulation system is usually accompanied by activation of fibrinolysis, and this holds true for pre-eclampsia.s'' Concentrations of fibrinogen-fibrin degradation products's' and soluble fibrinogen-fibrin complexesw are increased, while plasma plasminogen activator is unchanged, and tissue plasminogen activator is increased in plasma in pre-eclampsia.?' This increase in tissue plasminogen activator is accompanied by an increase in plasminogen activator inhibitors 1 and 2,91 a feature which had previously been noted as a reduction in urokinase activity.v' Plasminogen activator inhibitor 2 is produced only from the placenta and is not found in plasma from nonpregnant subjects. The increase in this placental plasminogen activator inhibitor is likely to reflect placental vascular damage and would predispose to local thrombosis by local inhibition of fibrinolysis in the placental bed. All studies are not consistent. de Boer et al. 92 found an increase in total plasminogen activator inhibitor in pre-eclampsia with a reduction in the placentally derived inhibitor component compared to normal. They also showed that low levels of placental plasminogen activator inhibitor are associated with poor fetal outcome and might, therefore, simply be a measure of placental function. The increase in fibrinopeptide B13 1-42 provides additional evidence of fibrinolytic activation. This peptide is generated by plasmin degradation of fibrin I, a soluble intermediate between fibrinogen and the spontaneously polymerizing fibrin II.
Plasminogen'<' and the inhibitor of plasmin, <X zantiplasmin.vs have also been found to be reduced, in keeping with fibrinolytic activation.
There is considerable evidence implicating platelets in the pathophysiology of pre-eclampsia. The circulating platelet count is reduced.vt reflecting a reduced platelet lifespan.w and an inverse relationship between platelet count and fibrinogen-fibrin degradation products has been noted, suggesting that the reduction in platelet count is due to increased platelet consumption associated with low grade DIC.83 The platelet specific protein 13-thromboglobulin, a marker of platelet activation in vivo, has also been found to be increased in pregnancy-induced hypertension.8z. 97.98 This correlates with proteinuria and serum creatinine,98 linking platelet activation with renal microvascular damage. The platelet content of 5-hydroxytryptamine is reduced in pre-eclampsia indicating platelet aggregation and stimulation of the platelet release reaction in vivo. Low platelet 5-hydroxytryptamine levels have also been associated with loss of platelet responsiveness to various aggregating agents in vitro. The explanation suggested for these findings is that platelets are activated in the microcirculation of the placenta, kidney and liver, release their products such as 13-thromboglobulin and 5-hydroxytryptamine, and then re-enter the system in an 'exhausted' state, unable to respond normally to aggregating agents and containing lower levels of 5-hydroxytryptamine. 99 In support of this hypothesis, placentae from patients with pre-eclampsia have been shown to contain high levels of 5-hydroxytryptamine, possibly of platelet origin. Other studies using platelet aggregation in platelet rich plasma have also noted 'platelet exhaustion' .100 This platelet exhaustion phenomenon has also been noted in molar pregnancy complicated by severe hypertension, where antiplatelet therapy corrected the hypofunctional platelet response.P! Platelets have also been shown to be less sensitive to the antiaggregatory effects of prostacyclin in pre-eclampsia, and this may contribute to the platelet consumption seen in this disease, especially as deficiency of endothelial prostacyclin production may coexist, as discussed below.
Increased platelet thromboxane A z production ex vivo has been shown to occur in pre-eclampsia complicated by intrauterine growth retardation.we Platelet aggregation in whole blood has been shown to be enhanced in pregnancy-induced hypertension compared to normal pregnant and nonpregnant women. 103 However, Louden et al. 104 found reduced platelet reactivity in whole blood in women with pre-eclampsia compared to normal controls, although there was no difference in TxB z production ex vivo. The report of Louden et al. 104 would be in keeping with platelet exhaustion as discussed above, and the differences in results between studies may reflect differences in patient severity, as platelet reactivity may vary according to the stage of the disease process with increased reactivity perhaps occurring in the early stages of the disease and platelet exhaustion in advanced disease. The role of platelets in the pathophysiology of the disease is emphasized by the recent success of anti platelet therapy in the treatment of high risk pregnancies. 105.106 Prostacyclin and the endothelium in preeclampsia
The endothelium plays a role in the control, not only of haemostasis and thrombosis, but also of vascular tone.f" It produces prostacyclin and endothelium derived relaxing factor (EDRF), which can inhibit the activation of platelets and neutrophils, and factors such as tissue plasminogen activator. These prevent or limit vascular damage. Conversely, the endothelium can render itself thrombogenic by secreting von Willebrand's factor, platelet activating factor and plasminogen activator inhibitor, which promote local coagulation and repair at the site of injury. The endothelium contributes to the regulation of vascular tone by release of prostacyclin and EDRF. Normally, the endothelium, platelets, and neutrophils will interact homeostatically but endothelial dysfunction may transform the endothelium from a non thrombogenic to a thrombogenic surface. There is now considerable evidence linking endothelial dysfunction to pre-eclampsia.
Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation. Maternal vascular prostacyclin production is reduced in preeclampsia.tv? and plasma and urinary prostacyclin metabolites are significantly lower, particularly in those with severe disease. 105-11 I Platelet thromboxane A 2 production may be increased in pre-eclampsia complicated by intrauterine growth retardation, 102 although Loudon et al. 104 found no difference in thromboxane production between normal and hypertensive pregnancies. Placentae taken from pregnancies complicated by pre-eclampsia have been shown to produce more thromboxane A 2 and less prostacyclin than those from normal pregnanciesuand their production of lipid peroxides is also increased.u-' Lipid peroxides which are formed from oxygen radicals
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Production of prostacyclin from placenta and cord vessels is reduced in pre-eclampsia. 11 Intact umbilical arteries taken from pregnancies complicated by pre-eclampsia have been shown to be unresponsive to a stimulus of prostacyclin production when compared with normal umbilical arteries,117,111l suggesting that the ability of the vascular endothelium to produce prostacyclin in response to a physiological stimulus is absent or substantially diminished in pre-eclampsia. Since the umbilical artery lacks any innervation it may depend on humoral control of blood flow by prostanolds'!? to maintain the low pressurehigh flow feto-placental circulation. Failure of the vessel to produce prostacyclin may result in increased umbilical artery resistance due to vasoconstriction, especially in the face of increased thromboxane production by the placenta, with resultant fetal compromise. The mechanism underlying prostacyclin deficiency in pre-eclampsia is unclear, but it may be due to reduced activity of enzyme systems required for its production. These enzymes could be inactivated by free radicals and lipid peroxides or proteolytic enzymes, making the prostacyclin deficiency a feature of endothelial damage and dysfunction. Other evidence of endothelial dysfunction and damage include elevated levels of fibrinectin, endothelin,12o.121 von WiIIebrand's factor and plasminogen activator inhibitors.
Neutrophils in pre-eclampsia
Neutrophils playa role in the pathophysiology of vascular damage in the nonpregnant situation. When neutrophils are activated they release a variety of substances capable of mediating vascular damage. These include the contents of neutrophil granules such as elastase and other proteases which can destroy the integrity of the endothelial cells, vascular basement membrane and subendothelial matrix. 122 Toxic oxygen species are also released, and can produce membrane lipid peroxidation, lysis of endothelial cells, and increased vascular permeability and reactivity.P? Leukotrienes which are synthesized and released following neutrophil activation will increase vascular permeability, induce vasoconstriction, and promote further neutrophil activation and adherence.P> Neutrophil elastase, a marker of neutrophil activation in vivo, is elevated in pre-eclampsia, indicating the presence of neutrophil activation,124 but this is confined to the maternal circulation.P" As elevated neutrophil elastase is found in both mild/moderate and severe disease, neutrophil activation may be an early part of the pathophysiological process of pre-eclarnpsia.P'
The elevated levels of neutrophil elastase seen in pre-eclampsia correlate with the increase in plasma von Willebrand factor and are associated with an increase in the endothelial derived vasoconstrictor endothelin .120 Neutrophil activation may therefore contribute directly to the vascular lesions seen in pre-eclampsia, such as those noted in the placental bed, and elastase positive neutrophils can be found in significantly higher numbers in the decidua of the placental bed in women with pre-eclampsia compared to normal pregnancies and this correlates with plasma urate, an established marker of disease activity. 126 In addition to directly bringing about endothelial damage, neutrophils will interact with platelets and the coagulation and complement systems. The activation of neutrophils in pre-eclampsia probably represents a secondary phenomenon, possibly triggered by the immunological mechanisms which have been implicated in the aetiology of this disorder, or simply secondary to vascular damage per se; nonetheless it may be an important contributor to the disease process.
It is of interest that neutrophil granule enzymes,127 reactive oxygen species ,128 and leukotrienes 129 have been shown to stimulate prostacyclin synthesis in endothelial cells. This is paradoxical as pre-eclampsia is associated with a deficiency of prostacyclin production which is thought to contribute to the platelet consumption and vasoconstriction seen in the condition. However, low concentrations of reactive oxygen species stimulate cyclo-oxygenase, which is essential for prostacyclin production, while higher concentrations will inhibit both this enzyme and prostacyclin synthase.P? Furthermore, high concentrations of reactive oxygen species can reorientate the arachidonic acid pathway in the cell away from the production of the cytoprotective and vascodilator agent prostacyclin towards thromboxane A 2.130 Thus, neutrophil activation may account for the necrotizing arteriopathy of pre-eclampsia which has been hitherto poorly explained, and may also explain several other features of the disease, such as prostacyclin deficiency and enhanced placental thromboxane production. Such neutrophil activation is not specific to pre-eclampsia as increased neutrophil elastase has been found in diabetic pregnancy.t» and in mothers with pregnancies complicated by intrauterine growth retardation. 132 It has also been noted that serum from women with pre-eclampsia has a greater cytotoxic effect on cultured endothelial cells than serum from normal pregnancies.P> Although the nature of this factor is unclear the authors suggest that, as this effect diminishes following delivery, it may be released from the placenta, but it could also be related to neutrophil activation. There is also evidence of a serum factor in pre-eclampsia which can increase vascular reactivity to angiotensin II in vitro.v» Endothelial damage and dysfunction is common to all of the pathological features of pre-eclampsia. It is likely to stimulate activation of neutrophils, platelets and the coagulation system, therefore promoting further endothelial damage. Thus, a positive feedback loop will result promoting vascular damage. The trigger which initiates this process is unclear, but it appears to originate in the placenta or uteroplacental bed as delivery results in disease regression. It is probably linked to the failure of trophoblast invasion which is characteristic of the disease. It is also obscure which facet of the vicious circle -endothelial damage, neutrophil activation or platelet activation, is triggered first.
Antiplatelet agents in pre-eclampsia
Prostacyclin has been employed in a therapeutic role in the treatment of severe pre-eclampsia, but it is only effective in the short-term and is impractical to use. 135,l36 Aspirin is the most practicable and effective agent presently available for clinical use as antiplatelet therapy. It has been used successfully in the prevention of pre-eclampsia and intrauterine growth retardation. The greatest problem with regard to its use in prophylaxis is the identification of patients who will require such therapy; this is especially true in pre-eclampsia, where those with the most severe disease are usually primigravidae.
Aspirin irreversibly inhibits cyclo-oxygenase which is required for prostaglandin and thromboxane production, therefore reducing thromboxane generation and platelet activation. However, the beneficial effects of aspirin may be offset by its inhibition of vascular prostacyclin production, as cyclo-oxygenase is required for the production of both substances. 137 This is obviously undesirable in pre-eclampsia. However, low dose aspirin may selectively block thromboxane production. Aspirin is extensively metabolized by the liver, and low doses given orally are thought to produce pharmacologically active drug concentrations in the portal circulation and not in the systemic circulation. Since platelet cyclooxygenase is irreversibly inhibited by aspirin, effective inhibition of platelet function would result as the platelet passes through the portal circulation, while, systemic vascular prostacyclin production might remain unaffected due to lower concentrations in the systemic circulation. In addition, the nucleated vascular endothelial cells, unlike anucleate platelets, can synthesize new protein and will replace any inactivated enzyme in a matter of hours,138 thus maintaining prostacyclin production. The efficacy of low dose aspirin in reducing thromboxane A z production has largely been demonstrated in nonpregnant patients with doses as low as 20 mg/day, reducing thromboxane A z production by up to 95%.139
However, it appears unlikely that any dose of aspirin can produce maximal inhibition of platelet thromboxane A z production without affecting prostacyclin production to some extent, although there appears to be a high degree of relative sparing of prostacyclin production with low-dose aspirin. 140 ,14 1 A major concern regarding the use of aspirin in pregnancy is that of aspirin reaching the fetus and impairing haemostasis or promoting closure of the ductus arteriosus, especially near to the time of delivery. Stuart et al. 14Z have documented haemostatic problems in neonates whose mothers received large doses (5-10 g) of aspirin up to five days before delivery. Ritter et al. 143 found that 37.5 mg of aspirin administered daily for two weeks prior to the expected date of delivery
The vascular pathophysiology of pre-eclampsia 137 significantly lowered maternal thromboxane A z but had no significant effect on thromboxane A z in neonatal blood or on prostacyclin production by the umbilical artery ex vivo. This differential effect is likely to reflect the extensive first pass metabolism of aspirin in the liver. However, significant levels of active aspirin can be detected in maternal plasma one hour after doses as low as 37.5 mg and 75 mg. 144 Chronic maternal intake of 60 mg of aspirin daily has been shown to have no significant effect on neonatal platelet function. 145 Sibai et al. 146 have also shown that chronic maternal therapy with aspirin (20-80 mg/day) has no effect on neonatal platelet function or on the ductus arteriosus. Thus, it would appear that low-dose aspirin has a selective effect on maternal platelet function, sparing fetal platelet function and prostacyclin production. It is also reassuring that there is no obvious effect on the ductus arteriosus. A further potential beneficial effect of aspirin is its ability to inhibit placental lipid peroxide production along with thromboxane production at drug concentrations which have no effect on prostacyclin production, 1D The inhibition of lipid peroxide production might contribute to the beneficial effect of aspirin on the disease process.
Several studies have examined the clinical efficacy of low-dose aspirin in the prevention of pre-eclampsia. The first was that of Beaufils et al. ,105 who randomized 102 women at high risk of pre-eclampsia to receive either no therapy or aspirin 150 mg in combination with dipyridamole 300 mg daily. The patients were selected on the basis of their past medical and obstetric histories, such as essential hypertension or a series of complicated pregnancies, and 99 of the women were parous. Spontaneous abortions and loss of patients to follow up left 93 patients for inclusion in the analysis. There was a significant reduction of pre-eclampsia and improved perinatal outcome in the treated group; six of 45 patients in the control group, compared to none of the 48 patients in the treatment group, developed preeclampsia. The incidence of growth retardation and fetal/neonatal loss was also significantly lower and there was a significant prolongation of pregnancy. There were no side effects except headache associated with dipyridamole therapy, and no haemorrhagic complications were encountered. This study, however, used relatively small numbers of patients and the groups were unbalanced with regard to several variables of prognostic significance. In addition, two drugs, aspirin and dipyridamole, were tested in combination, although there is no evidence to suggest that dipyridamole will enhance the clinical effect of aspirin alone. Finally, 150 mg/day of aspirin was used which is substantially more than is required to produce effective inhibition of platelet thromboxane A 2 production. Wallen burg et a/. 106 reported their findings on low-dose (60 mg/day) aspirin therapy in women at risk of pre-eclampsia. Patients were selected for inclusion in the doubleblind, placebo-controlled trial by screening 207 women with angiotensin II infusions. The 46 who were sensitive to angiotensin II at 28 weeks gestation were recruited to the study and 44 were included in the analysis. While there was a significant reduction in the development of hypertensive complications (two of 21 in the treatment group versus 12 of 23 in the placebo group), there was no significant effect on length of gestation at delivery or number of growth retarded infants, although there was a tendency to a lower incidence of these conditions in the treatment group. Schiff et a/. 147 selected patients on the basis of the 'roll over test',148 although the predictive value of this test is disputed.v'? After blood pressure has been measured in the left lateral position, the patient rolls on to her back, and after a few minutes the blood pressure measurement is repeated. An increase in diastolic blood pressure of more than 15 mmHg after 'rolling over' is considered positive. After screening 791 women, 65 with positive tests were randomized to receive aspirin 100 mg/day or placebo in a prospective double-blind manner. The patients were of mixed parity. There was a significant reduction in hypertensive complications, an increase in gestation at delivery, and an increase in adjusted birthweight centile compared to the placebo group. There were no maternal side effects and no maternal or neonatal haemorrhagic effects. Benigni et a/. 150 studied the effects of 60 mg aspirin or placebo in 33 women judged to be at risk of pre-eclampsia on the basis of their past obstetric history or past medical history such as chronic hypertension. Treatment was started from the 12th week single-blind. The infants of the treatment group had a significantly greater birthweight and longer gestation than those of the placebo group, but no other differences were noted. Aspirin also significantly and substantially reduced urinary thromboxane B 2 levels, but there was no effect on prostacyclin production, measured as its metabolites in urine, indicating that a selective effect on platelets was occurring, with sparing of the endothelium. Again, no haemorrhagic complications were found in the newborn infants, although there was a significant reduction in serum thromboxane B 2 in the neonates in the treatment group, although this was not as great as the reduction which occurred in the mothers. However, this suggests that even with a dose as low as 60 mg aspirin/day, the fetus is still exposed to some active aspirin.
Since pre-eclampsia is associated with excess TxA 2 and deficient PGI 2 production, it would seem logical to consider the role of thromboxane synthetase inhibitors which would have a more specific and selective effect than aspirin. In addition, they may divert the cycloendoperoxides PGG 2 and PGH 2 produced in the platelets to the vessel wall where they could potentially be converted to prostacyclin by prostacyclin synthetase, an effect which would be most prominent at sites of platelet activation thereby limiting vascular damage. However, if this conversion were not to occur, for example if the prostacyclin synthetase is damaged, then the cycloendoperoxides will act as thromboxane mimetics provoking platelet aggregation and vasoconstriction. This latter effect may explain why these agents have not been as successful in the treatment of vascular disease as initially hoped. There is very limited experience of their use in pregnancy. Van Assche and Spitz 15 1 and van Assche et a/. 152 have reported on 11 pregnancies complicated by severe pre-eclampsia treated with the thromboxane synthetase inhibitor dazoxiben. A mean prolongation of pregnancy of four weeks and three days was achieved, with a mean gestation at starting therapy of 27 weeks. 151 In addition, many of the patients required their antihypertensive therapy to be reduced or withdrawn after dazoxiben was commenced. Furthermore, one patient with HELLP syndrome normalized her biochemical and haematological parameters after starting dazoxiben.P! However, the effects of such treatment remain anecdotal.
Antihypertensive therapy and antiplatelet effects
Antihypertensive agents are increasingly being used in the treatment of pre-eclampsia. These agents will relax vascular smooth muscle. As platelets have contractile responses of their cytoskeleton related to Ca2+ availability similar to vascular smooth muscle, we examined the hypothesis that antihypertensive agents might influence platelet function. The effects of adrenoceptor antagonists on platelet aggregation in platelet rich plasma were studied in vitro. The drugs assessed differed in their receptor specificities, membrane stabilizing activity, intrinsic sympathomimetic activity and lipid solubility. Labetalol (a!, 13 1, 132 blocker), pindolol (131' 132 blocker with intrinsic sympathomimetic activity) and
propranolol (13 1 , 132 blocker) inhibited platelet aggregation in a dose dependent manner. 153.154 This effect was independent of any alpha or beta adrenoceptor blocking activity as atenolol (13 1 blocker), metoprolol (13 1 blocker), timolol (13 1, 132 blocker) and prazosin (a l blocker) were without effect. This inhibitory effect appeared to be related to the lipid solubility and membrane stabilizing properties of the agents studied as these properties were common to all three effective agents. These three drugs also inhibited thromboxane production in platelet rich plasma and whole blood 153,155 and this appeared to be due to inhibition of phospholipase A 2 activity. 153 Since these agents appear to inhibit phospholipase activity they might also inhibit prostacyclin production which also depends on arachidonic acid being released from the cell membrane; however, labetalol and propranolol have little effect on vascular prostacyclin production. 156 This suggests that there may be some degree of selectivity between the effects of these agents on platelets and the vessel wall. In addition, these drugs acted synergistically with both exogenous prostacyclin and prostacyclin derived from umbilical arterial tissue to inhibit platelet aggregation in vitro.i» Such a synergistic effect might allow these drugs to compensate for the deficiency of prostacyclin by potentiating the effects of any residual prostacyclin produced by the endothelium. This ancillary effect may be of value when these agents are employed as antihypertensive
The vascular pathophysiology of pre-eclampsia 139 therapy in pre-eclampsia. There is also evidence to suggest that labetalol has platelet protective effects in vivo. Platelet count has been shown to increase in women with severe disease after one week's therapy with labetalolt>? and platelet aggregation can be reduced ex vivo. ISH Sibai et al. 159 found no change in platelet count in women treated with labetalol compared to those who were not, however the initial platelet count was not suppressed in these women suggesting that platelet consumption might not have been a significant feature in the patients studied, These effects are not confined to the adrenoceptor antagonists; calcium channel blocking agents have a similar inhibitory effect on platelet aggregation in vitro160.161 and platelet consumption in ViVO,162 although other studies with nifedipine have not noted an in vivo effect. 163 The vasodilator hydralazine can also inhibit thromboxane production in vitro.164
Combinations of an adrenoceptor antagonist or a calcium channel blocking agent and a low dose of aspirin also act synergistically to inhibit platelet function.w' This synergism may be due to the sequential inhibition of phospholipases and cycle-oxygenase which are both required for thromboxane production. Such a therapeutic strategy might be of value in preeclampsia, combining the antihypertensive and antiplatelet properties of adrenoceptor antagonists or calcium channel blockers with the more potent antiplatelet properties of aspirin. It may also allow even lower doses of aspirin to be used. Whether or not the antiplatelet effects of such antihypertensive therapy are of any clinical value remains to be established, but there are at least good theoretical reasons to employ an antihypertensive agent with antiplatelet properties in the treatment of pre-eclampsia.
Conclusion
Pre-eclampsia is characterized by vascular damage which appears to be brought about by endothelial dysfunction and activation of platelets, neutrophils and the coagulation system. Although the aetiology of this condition is unclear, we have a sufficient understanding of the pathophysiological processes involved, to attempt to intervene therapeutically. The best option presently available to prevent or ameliorate the disease process is low-12 dose aspirin. We must still, however, consider other therapeutic options in a controlled and 13 scientific manner if we wish to impact upon the clinical problem of pre-eclampsia. Further examination of the pathophysiological processes 14 and their modification is also essential to identify new areas where therapeutic or prophylactic strat-15 egies can be used. 16 
